[Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].
Kusumoto
Keiji
K
Kusumoto_Keiji@takeda.co.jp
Mori
Mitsuhiro
M
Tanokashira
Junichi
J
Totsuka
Nobuo
N
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D015195:Drug Design; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D013607:Tablets; D013777:Tetrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D013607:Tablets; D013777:Tetrazoles; D006852:Hydrochlorothiazide; C077793:candesartan cilexetil